{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:38:33Z","timestamp":1793680713837,"version":"4.5.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T00:00:00Z","timestamp":1598400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T00:00:00Z","timestamp":1598400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Controlling metastasis is essential for improving the prognosis of patients with gastric cancer (GC). Here, we aimed to identify a molecule required for GC metastasis and to investigate its potential utility as a target for the development of therapeutic antibodies (Abs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Transcriptome and bioinformatics analyses of human GC cell lines identified the neuronal pentraxin receptor (\n                      <jats:italic>NPTXR<\/jats:italic>\n                      ) as a candidate molecule.\n                      <jats:italic>NPTXR<\/jats:italic>\n                      function was probed by modulating its expression in GC cells and assessing the effects on intracellular signaling and malignant behaviors in vitro and in mouse xenograft models. We also generated anti-NPTXR Abs and\n                      <jats:italic>Nptxr<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>\u2212\/\u2212<\/jats:italic>\n                      <\/jats:sup>\n                      mice, and assessed the clinical significance of\n                      <jats:italic>NPTXR<\/jats:italic>\n                      expression in GC specimens.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      <jats:italic>NPTXR<\/jats:italic>\n                      mRNA expression in clinical specimens was associated with disease progression and was significantly higher in tissues from GC patients with distant metastasis compared with those without.\n                      <jats:italic>NPTXR<\/jats:italic>\n                      regulated expression of genes involved in metastatic behaviors as well as activation of the PI3K\u2013AKT\u2013mTOR, FAK\u2013JNK, and YAP signaling pathways.\n                      <jats:italic>NPTXR<\/jats:italic>\n                      silencing promoted caspase-mediated apoptosis and attenuated GC cell proliferation, cell cycle progression, migration, invasion, adhesion, stem cell-like properties, and resistance to 5-fluorouracil in vitro, and also inhibited the tumorigenicity of GC cells in vivo. Anti-\n                      <jats:italic>NPTXR<\/jats:italic>\n                      Abs inhibited GC peritoneal metastasis in mice.\n                      <jats:italic>Nptxr<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>\u2212\/\u2212<\/jats:italic>\n                      <\/jats:sup>\n                      mice showed no abnormalities in reproduction, development, metabolism, or motor function.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      <jats:italic>NPTXR<\/jats:italic>\n                      plays an essential role in controlling the malignant behavior of GC cells in vitro and in vivo.\n                      <jats:italic>NPTXR<\/jats:italic>\n                      -targeting Abs may thus have utility as novel diagnostic tools and\/or treatment modalities for GC.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12943-020-01251-0","type":"journal-article","created":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T01:02:32Z","timestamp":1598403752000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Therapeutic monoclonal antibody targeting of neuronal pentraxin receptor to control metastasis in gastric cancer"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5464-3819","authenticated-orcid":false,"given":"Mitsuro","family":"Kanda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Sawaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Umeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Miwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruyoshi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chie","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamichi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Iguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahisa","family":"Katsuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Kodera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,26]]},"reference":[{"key":"1251_CR1","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1016\/S0140-6736(16)30354-3","volume":"388","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet. 2016;388:2654\u201364.","journal-title":"Lancet"},{"key":"1251_CR2","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.cgh.2019.07.045","volume":"18","author":"AP Thrift","year":"2020","unstructured":"Thrift AP, El-Serag HB. Burden of gastric Cancer. Clin Gastroenterol Hepatol. 2020;18:534\u201342.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1251_CR3","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15:1224\u201335.","journal-title":"Lancet Oncol"},{"key":"1251_CR4","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S1470-2045(16)00175-3","volume":"17","author":"K Muro","year":"2016","unstructured":"Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, Eder JP, Golan T, Le DT, Burtness B, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016;17:717\u201326.","journal-title":"Lancet Oncol"},{"key":"1251_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0140-6736(18)31257-1","volume":"392","author":"K Shitara","year":"2018","unstructured":"Shitara K, Ozguroglu M, Bang YJ, Di Bartolomeo M, Mandala M, Ryu MH, Fornaro L, Olesinski T, Caglevic C, Chung HC, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392:123\u201333.","journal-title":"Lancet"},{"key":"1251_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","volume":"383","author":"CS Fuchs","year":"2014","unstructured":"Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry DR, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31\u20139.","journal-title":"Lancet"},{"key":"1251_CR7","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s10120-019-00995-z","volume":"23","author":"M Kanda","year":"2020","unstructured":"Kanda M, Suh YS, Park DJ, Tanaka C, Ahn SH, Kong SH, Lee HJ, Kobayashi D, Fujiwara M, Shimada H, et al. Serum levels of ANOS1 serve as a diagnostic biomarker of gastric cancer: a prospective multicenter observational study. Gastric Cancer. 2020;23:203\u201311.","journal-title":"Gastric Cancer"},{"key":"1251_CR8","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1053\/j.gastro.2013.05.010","volume":"145","author":"Z Lei","year":"2013","unstructured":"Lei Z, Tan IB, Das K, Deng N, Zouridis H, Pattison S, Chua C, Feng Z, Guan YK, Ooi CH, et al. Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. Gastroenterology. 2013;145:554\u201365.","journal-title":"Gastroenterology"},{"key":"1251_CR9","doi-asserted-by":"crossref","unstructured":"Tan IB, Ivanova T, Lim KH, Ong CW, Deng N, Lee J, Tan SH, Wu J, Lee MH, Ooi CH, et al: Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology 2011, 141:476\u2013485, 85 e1\u201311.","DOI":"10.4016\/32808.01"},{"key":"1251_CR10","doi-asserted-by":"crossref","unstructured":"Lee SJ, Wei M, Zhang C, Maxeiner S, Pak C, Calado Botelho S, Trotter J, Sterky FH, S\u00fcdhof TC. Presynaptic Neuronal Pentraxin Receptor Organizes Excitatory and Inhibitory Synapses. J Neurosci. 2017;37:1062\u201380.","DOI":"10.1523\/JNEUROSCI.2768-16.2016"},{"key":"1251_CR11","doi-asserted-by":"publisher","first-page":"21488","DOI":"10.1074\/jbc.272.34.21488","volume":"272","author":"DC Dodds","year":"1997","unstructured":"Dodds DC, Omeis IA, Cushman SJ, Helms JA, Perin MS. Neuronal pentraxin receptor, a novel putative integral membrane pentraxin that interacts with neuronal pentraxin 1 and 2 and taipoxin-associated calcium-binding protein 49. J Biol Chem. 1997;272:21488\u201394.","journal-title":"J Biol Chem"},{"key":"1251_CR12","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.1158\/0008-5472.CAN-15-0649","volume":"75","author":"A Bartolini","year":"2015","unstructured":"Bartolini A, Di Paolo D, Noghero A, Murgia D, Sementa AR, Cilli M, Pasqualini R, Arap W, Bussolino F, Ponzoni M, et al. The neuronal Pentraxin-2 pathway is an unrecognized target in human neuroblastoma, which also offers prognostic value in patients. Cancer Res. 2015;75:4265\u201371.","journal-title":"Cancer Res"},{"key":"1251_CR13","doi-asserted-by":"publisher","first-page":"49322","DOI":"10.18632\/oncotarget.10337","volume":"7","author":"AM Szasz","year":"2016","unstructured":"Szasz AM, Lanczky A, Nagy A, Forster S, Hark K, Green JE, Boussioutas A, Busuttil R, Szabo A, Gyorffy B. Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. Oncotarget. 2016;7:49322\u201333.","journal-title":"Oncotarget"},{"key":"1251_CR14","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1097\/SLA.0000000000002096","volume":"267","author":"M Kanda","year":"2018","unstructured":"Kanda M, Shimizu D, Tanaka H, Tanaka C, Kobayashi D, Hayashi M, Iwata N, Niwa Y, Yamada S, Fujii T, et al. Significance of SYT8 for the detection, prediction, and treatment of peritoneal metastasis from gastric Cancer. Ann Surg. 2018;267:495\u2013503.","journal-title":"Ann Surg"},{"key":"1251_CR15","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.21873\/invivo.11669","volume":"33","author":"T Miwa","year":"2019","unstructured":"Miwa T, Kanda M, Umeda S, Tanaka H, Shimizu D, Tanaka C, Kobayashi D, Hayashi M, Yamada S, Nakayama G, et al. Establishment of peritoneal and hepatic metastasis mouse Xenograft models using gastric Cancer cell lines. Vivo. 2019;33:1785\u201392.","journal-title":"Vivo"},{"key":"1251_CR16","doi-asserted-by":"publisher","first-page":"5355","DOI":"10.1038\/s41388-018-0335-8","volume":"37","author":"M Kanda","year":"2018","unstructured":"Kanda M, Tanaka H, Shimizu D, Miwa T, Umeda S, Tanaka C, Kobayashi D, Hattori N, Suenaga M, Hayashi M, et al. SYT7 acts as a driver of hepatic metastasis formation of gastric cancer cells. Oncogene. 2018;37:5355\u201366.","journal-title":"Oncogene"},{"key":"1251_CR17","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.cell.2013.04.025","volume":"153","author":"H Wang","year":"2013","unstructured":"Wang H, Yang H, Shivalila CS, Dawlaty MM, Cheng AW, Zhang F, Jaenisch R. One-step generation of mice carrying mutations in multiple genes by CRISPR\/Cas-mediated genome engineering. Cell. 2013;153:910\u20138.","journal-title":"Cell"},{"key":"1251_CR18","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S0896-6273(02)00834-6","volume":"35","author":"M Katsuno","year":"2002","unstructured":"Katsuno M, Adachi H, Kume A, Li M, Nakagomi Y, Niwa H, Sang C, Kobayashi Y, Doyu M, Sobue G. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron. 2002;35:843\u201354.","journal-title":"Neuron"},{"key":"1251_CR19","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1136\/gutjnl-2014-308932","volume":"65","author":"SM Wang","year":"2016","unstructured":"Wang SM, Tie J, Wang WL, Hu SJ, Yin JP, Yi XF, Tian ZH, Zhang XY, Li MB, Li ZS, et al. POU2F2-oriented network promotes human gastric cancer metastasis. Gut. 2016;65:1427\u201338.","journal-title":"Gut"},{"key":"1251_CR20","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nrclinonc.2014.138","volume":"11","author":"M Razzak","year":"2014","unstructured":"Razzak M. Genetics: new molecular classification of gastric adenocarcinoma proposed by the Cancer genome atlas. Nat Rev Clin Oncol. 2014;11:499.","journal-title":"Nat Rev Clin Oncol"},{"key":"1251_CR21","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1002\/ijc.30895","volume":"141","author":"X Liu","year":"2017","unstructured":"Liu X, Zhang X, Zhang Z, Chang J, Wang Z, Wu Z, Wang C, Sun Z, Ge X, Geng R, et al. Plasma microRNA-based signatures to predict 3-year postoperative recurrence risk for stage II and III gastric cancer. Int J Cancer. 2017;141:2093\u2013102.","journal-title":"Int J Cancer"},{"key":"1251_CR22","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.brainres.2009.01.058","volume":"1265","author":"GN Yin","year":"2009","unstructured":"Yin GN, Lee HW, Cho JY, Suk K. Neuronal pentraxin receptor in cerebrospinal fluid as a potential biomarker for neurodegenerative diseases. Brain Res. 2009;1265:158\u201370.","journal-title":"Brain Res"},{"key":"1251_CR23","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1093\/neuonc\/noq074","volume":"12","author":"F Andreiuolo","year":"2010","unstructured":"Andreiuolo F, Puget S, Peyre M, Dantas-Barbosa C, Boddaert N, Philippe C, Mauguen A, Grill J, Varlet P. Neuronal differentiation distinguishes supratentorial and infratentorial childhood ependymomas. Neuro-Oncology. 2010;12:1126\u201334.","journal-title":"Neuro-Oncology"},{"key":"1251_CR24","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.neuron.2015.02.020","volume":"85","author":"KA Pelkey","year":"2015","unstructured":"Pelkey KA, Barksdale E, Craig MT, Yuan X, Sukumaran M, Vargish GA, Mitchell RM, Wyeth MS, Petralia RS, Chittajallu R, et al. Pentraxins coordinate excitatory synapse maturation and circuit integration of parvalbumin interneurons. Neuron. 2015;85:1257\u201372.","journal-title":"Neuron"},{"key":"1251_CR25","doi-asserted-by":"crossref","unstructured":"Kirkpatrick LL, Matzuk MM, Dodds DC, Perin MS. Biochemical interactions of the neuronal pentraxins. Neuronal pentraxin (NP) receptor binds to taipoxin and taipoxin-associated calcium-binding protein 49 via NP1 and NP2. J Biol Chem. 2000;275:17786-92.","DOI":"10.1074\/jbc.M002254200"},{"key":"1251_CR26","doi-asserted-by":"publisher","first-page":"4796","DOI":"10.1158\/0008-5472.CAN-14-0210","volume":"74","author":"CA von Roemeling","year":"2014","unstructured":"von Roemeling CA, Radisky DC, Marlow LA, Cooper SJ, Grebe SK, Anastasiadis PZ, Tun HW, Copland JA. Neuronal pentraxin 2 supports clear cell renal cell carcinoma by activating the AMPA-selective glutamate receptor-4. Cancer Res. 2014;74:4796\u2013810.","journal-title":"Cancer Res"},{"key":"1251_CR27","doi-asserted-by":"publisher","first-page":"e0141090","DOI":"10.1371\/journal.pone.0141090","volume":"10","author":"E Acikgoz","year":"2015","unstructured":"Acikgoz E, Guven U, Duzagac F, Uslu R, Kara M, Soner BC, Oktem G. Enhanced G2\/M arrest, Caspase Related Apoptosis and Reduced E-Cadherin Dependent Intercellular Adhesion by Trabectedin in Prostate Cancer Stem Cells. PLoS One. 2015;10:e0141090.","journal-title":"PLoS One"},{"key":"1251_CR28","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.3390\/ijms11062267","volume":"11","author":"XD Liu","year":"2010","unstructured":"Liu XD, Fan RF, Zhang Y, Yang HZ, Fang ZG, Guan WB, Lin DJ, Xiao RZ, Huang RW, Huang HQ, et al. Down-regulation of telomerase activity and activation of caspase-3 are responsible for Tanshinone I-induced apoptosis in monocyte leukemia cells in vitro. Int J Mol Sci. 2010;11:2267\u201380.","journal-title":"Int J Mol Sci"},{"key":"1251_CR29","doi-asserted-by":"publisher","first-page":"287358","DOI":"10.1155\/2013\/287358","volume":"2013","author":"A Samykutty","year":"2013","unstructured":"Samykutty A, Shetty AV, Dakshinamoorthy G, Kalyanasundaram R, Zheng G, Chen A, Bosland MC, Kajdacsy-Balla A, Gnanasekar M. Vitamin k2, a naturally occurring menaquinone, exerts therapeutic effects on both hormone-dependent and hormone-independent prostate cancer cells. Evid Based Complement Alternat Med. 2013;2013:287358.","journal-title":"Evid Based Complement Alternat Med"},{"key":"1251_CR30","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.3892\/mmr.2015.4717","volume":"13","author":"CH Cheng","year":"2016","unstructured":"Cheng CH, Cheng YP, Chang IL, Chen HY, Wu CC, Hsieh CP. Dodecyl gallate induces apoptosis by upregulating the caspase-dependent apoptotic pathway and inhibiting the expression of anti-apoptotic Bcl-2 family proteins in human osteosarcoma cells. Mol Med Rep. 2016;13:1495\u2013500.","journal-title":"Mol Med Rep"},{"key":"1251_CR31","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1530\/ERC-13-0150","volume":"20","author":"G Poli","year":"2013","unstructured":"Poli G, Guasti D, Rapizzi E, Fucci R, Canu L, Bandini A, Cini N, Bani D, Mannelli M, Luconi M. Morphofunctional effects of mitotane on mitochondria in human adrenocortical cancer cells. Endocr Relat Cancer. 2013;20:537\u201350.","journal-title":"Endocr Relat Cancer"},{"key":"1251_CR32","first-page":"43","volume":"2018","author":"L Mele","year":"1692","unstructured":"Mele L, Liccardo D, Tirino V. Evaluation and isolation of Cancer stem cells using ALDH activity assay. Methods Mol Biol. 1692;2018:43\u20138.","journal-title":"Methods Mol Biol"},{"key":"1251_CR33","doi-asserted-by":"publisher","first-page":"33403","DOI":"10.18632\/oncotarget.23607","volume":"9","author":"Y Zhou","year":"2018","unstructured":"Zhou Y, Xia L, Wang H, Oyang L, Su M, Liu Q, Lin J, Tan S, Tian Y, Liao Q, Cao D. Cancer stem cells in progression of colorectal cancer. Oncotarget. 2018;9:33403\u201315.","journal-title":"Oncotarget"},{"key":"1251_CR34","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1097\/JTO.0000000000000592","volume":"10","author":"M Tessema","year":"2015","unstructured":"Tessema M, Yingling CM, Picchi MA, Wu G, Liu Y, Weissfeld JL, Siegfried JM, Tesfaigzi Y, Belinsky SA. Epigenetic repression of CCDC37 and MAP 1B links chronic obstructive pulmonary disease to lung Cancer. J Thorac Oncol. 2015;10:1181\u20138.","journal-title":"J Thorac Oncol"},{"key":"1251_CR35","first-page":"266","volume":"81","author":"T Yasuda","year":"2017","unstructured":"Yasuda T, Iizuka K, Fukuda M, Takeda J, Natsume T, Horikawa Y, Gadoth A, Kryzer TJ, Fryer J, McKeon A, et al. Microtubule-associated protein 1B: novel paraneoplastic biomarker. Sci Rep. 2017;81:266\u201377.","journal-title":"Sci Rep"},{"key":"1251_CR36","doi-asserted-by":"crossref","unstructured":"Qin Z, Wang Y, Tang J, Zhang L, Li R, Xue J, Han P, Wang W, Qin C, Xing Q, et al. High LINC01605 expression predicts poor prognosis and promotes tumor progression via up-regulation of MMP9 in bladder cancer. Biosci Rep. 2018;38.","DOI":"10.1042\/BSR20180562"},{"key":"1251_CR37","first-page":"2221","volume":"42","author":"X Wang","year":"2018","unstructured":"Wang X, Wang B, Xie J, Hou D, Zhang H, Huang H. Melatonin inhibits epithelialtomesenchymal transition in gastric cancer cells via attenuation of IL1beta\/NFkappaB\/MMP2\/MMP9 signaling. Int J Mol Med. 2018;42:2221\u20138.","journal-title":"Int J Mol Med"},{"key":"1251_CR38","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00018-005-5386-7","volume":"63","author":"AG McLennan","year":"2006","unstructured":"McLennan AG. The Nudix hydrolase superfamily. Cell Mol Life Sci. 2006;63:123\u201343.","journal-title":"Cell Mol Life Sci"},{"key":"1251_CR39","doi-asserted-by":"publisher","first-page":"12261","DOI":"10.3748\/wjg.v21.i43.12261","volume":"21","author":"SS Singh","year":"2015","unstructured":"Singh SS, Yap WN, Arfuso F, Kar S, Wang C, Cai W, Dharmarajan AM, Sethi G, Kumar AP. Targeting the PI3K\/Akt signaling pathway in gastric carcinoma: a reality for personalized medicine? World J Gastroenterol. 2015;21:12261\u201373.","journal-title":"World J Gastroenterol"},{"key":"1251_CR40","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1002\/ijc.31561","volume":"143","author":"M Shibata","year":"2018","unstructured":"Shibata M, Ham K, Hoque MO. A time for YAP1: tumorigenesis, immunosuppression and targeted therapy. Int J Cancer. 2018;143:2133\u201344.","journal-title":"Int J Cancer"},{"key":"1251_CR41","doi-asserted-by":"publisher","first-page":"7617","DOI":"10.1038\/s41598-019-44098-2","volume":"9","author":"JM Murphy","year":"2019","unstructured":"Murphy JM, Jeong K, Rodriguez YAR, Kim JH, Ahn EE, Lim SS. FAK and Pyk2 activity promote TNF-\u03b1 and IL-1\u03b2-mediated pro-inflammatory gene expression and vascular inflammation. Sci Rep. 2019;9:7617.","journal-title":"Sci Rep"},{"key":"1251_CR42","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.bbrc.2018.05.110","volume":"501","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Peng X, Zheng Q. Ropivacaine inhibits the migration of esophageal cancer cells via sodium-channel-independent but prenylation-dependent inhibition of Rac1\/JNK\/paxillin\/FAK. Biochem Biophys Res Commun. 2018;501:1074\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"1251_CR43","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/nrc3792","volume":"14","author":"FJ Sulzmaier","year":"2014","unstructured":"Sulzmaier FJ, Jean C, Schlaepfer DD. FAK in cancer: mechanistic findings and clinical applications. Nat Rev Cancer. 2014;14:598\u2013610.","journal-title":"Nat Rev Cancer"},{"key":"1251_CR44","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1128\/MCB.24.10.4361-4371.2004","volume":"24","author":"E Kurenova","year":"2004","unstructured":"Kurenova E, Xu LH, Yang X, Baldwin AS Jr, Craven RJ, Hanks SK, Liu ZG, Cance WG. Focal adhesion kinase suppresses apoptosis by binding to the death domain of receptor-interacting protein. Mol Cell Biol. 2004;24:4361\u201371.","journal-title":"Mol Cell Biol"},{"key":"1251_CR45","doi-asserted-by":"crossref","unstructured":"Martin TC, Ilieva KM, Visconti A, Beaumont M, Kiddle SJ, Dobson RJB, Mangino M, Lim EM, Pezer M, Steves CJ, et al. Dysregulated antibody, natural killer cell and immune mediator profiles in autoimmune thyroid diseases. Cells. 2020;9.","DOI":"10.3390\/cells9030665"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-020-01251-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-020-01251-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-020-01251-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T19:18:48Z","timestamp":1629919128000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-020-01251-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,26]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1251"],"URL":"https:\/\/doi.org\/10.1186\/s12943-020-01251-0","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,26]]},"assertion":[{"value":"23 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the institutional review board\/ethics committee of the Nagoya University Hospital (2014\u20130043).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors give consent for the publication of manuscript in Molecular Cancer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there is no potential competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"131"}}